Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for ABEO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
March 31, 2026 59.12%
December 31, 2025 31.73%
September 30, 2025
June 30, 2025 -117.0%
March 31, 2025
December 31, 2024
September 30, 2024
June 30, 2024
March 31, 2024
December 31, 2023
September 30, 2023
June 30, 2023 76.06%
March 31, 2023
December 31, 2022 -1.38K%
September 30, 2022
June 30, 2022 -37.00%
March 31, 2022 -221.7%
December 31, 2021 60.13%
September 30, 2021
June 30, 2021
March 31, 2021
December 31, 2020 72.00%
September 30, 2020 0.00%
June 30, 2020
March 31, 2020
Date Value
December 31, 2019
September 30, 2019
June 30, 2019
March 31, 2019
September 30, 2018 0.00%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017 0.00%
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016 0.00%
September 30, 2016 0.00%
June 30, 2016 0.00%
March 31, 2016 0.00%
December 31, 2015 0.00%
September 30, 2015 0.00%
June 30, 2015 0.00%
March 31, 2015 0.00%
December 31, 2014 96.15%
September 30, 2014 99.58%
June 30, 2014 99.60%
March 31, 2014 0.00%
December 31, 2013 99.38%
September 30, 2013 96.30%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 98.25%
Forum Markets, Inc. 83.46%
Precigen, Inc. 87.63%
PDS Biotechnology Corp. --
ACADIA Pharmaceuticals, Inc. 90.75%

Gross Profit Margin (Quarterly) Related Metrics